Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early home treatment strategies for mild or moderate COVID-19
2020-005890-29Phase 3Terminated
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Mar 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Paracetamol arm, Celecoxib arm and Paracetamol + enoxaparin arm (3 arms). Primary endpoint: Clinical worsening by day 5 to 10 after treatment start. Started Mar 2021; status: terminated.
02
Drugs
acetaminophencelecoxibenoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005890-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005890-29.